Background
Methods
Design and study population
Statistical analysis
Results
Demographics of centenarians
Men | Women | P value | |
---|---|---|---|
Socio-demographics | |||
N | 351 | 1329 | <0.001 |
Mean age, yearsa | 101.7 (101.5–101.9) | 101.6 (101.5–101.7) | n.s.b |
Urban residence, % | 58.7% | 56.7% | n.s. |
Deprivation index, %c | n.s. | ||
Q1 | 29.1% | 31.1% | |
Q2 | 23.7% | 22.8% | |
Q3 | 24.0% | 20.7% | |
Q4 | 23.1% | 25.6% | |
Clinical information | |||
Without chronic diseases, % | 7.6% | 5.2% | n.s. |
Chronic diseases, meana | 3.97 (3.65–4.28) | 3.97 (3.81–4.12) | n.s. |
With multimorbidity, % | 78.0% | 81.3% | n.s. |
Without chronic medications, % | 8.1% | 6.4% | n.s. |
Chronic drugs, meana | 4.94 (4.56–5.33) | 4.77 (4.58–4.95) | n.s. |
With polypharmacy, %d | 49.8% | 49.5% | n.s. |
With potentially inappropriate medications, %a,e | 71.1% | 72.3% | n.s. |
Potentially inappropriate medications, meana | 1.32 (1.19–1.45) | 1.36 (1.29–1.43) | n.s. |
Anticholinergic Drug Scale score, % | n.s. | ||
0 | 50.6% | 50.2% | |
1 | 28.2% | 29.5% | |
2 | 12.4% | 12.3% | |
≥3 | 8.8% | 8.0% | |
Anticholinergic Cognitive Burden score, % | n.s. | ||
0 | 55.3% | 52.3% | |
1 | 26.0% | 28.8% | |
2 | 6.2% | 8.5% | |
≥3 | 12.5% | 10.4% | |
Healthcare use | |||
Users of primary care services, % | 76.1% | 79.4% | n.s. |
Visits to GPf, meana | 10.6 (9.4–11.7) | 10.8 (10.2–11.5) | n.s. |
Visits to nurse, meana | 9.3 (7.8–10.9) | 12.1 (10.9–13.3) | n.s. |
Users of specialities, % | 24.5% | 22.3% | n.s. |
Visits to a specialist, meana | 2.79 (2.16–3.43) | 2.72 (2.44–2.99) | n.s. |
Different specialties visited, meana | 1.37 (1.23–1.51) | 1.47 (1.37–1.57) | n.s. |
Users of hospital, % | 14.8% | 12.1% | n.s. |
Total hospital admissions, meana | 1.35 (1.17–1.52) | 1.34 (1.23–1.45) | n.s. |
Scheduled hospital admissions, meana | 0.06 (0.00–0.12) | 0.12 (0.06–0.17) | n.s. |
Length of stay in days, meana | 10.0 (7.9–12.0) | 11.6 (10.3–13.0) | n.s. |
Users of emergency room, % | 11.7% | 8.3% | n.s. |
Visits to emergency room, meana | 1.80 (1.40–2.21) | 1.45 (1.28–1.62) | n.s. |
Disease burden in centenarians
EDCa code | Chronic condition | Men (%) | Women (%) | P value |
---|---|---|---|---|
CAR14/15 | Hypertension | 46.8 | 58.4 | <0.001 |
REC03 | Chronic ulcer of the skin | 22.0 | 29.7 | <0.01 |
NUR05 | Cerebrovascular disease | 22.3 | 21.3 | n.s.b |
CAR05 | Congestive heart failure | 20.2 | 20.3 | n.s. |
NUR24 | Dementia | 12.8 | 21.7 | <0.001 |
MUS03 | Degenerative joint disease | 13.2 | 18.1 | <0.05 |
GSU08 | Varicose veins of lower extremities | 8.6 | 16.5 | <0.001 |
EYE06 | Cataract, aphakia | 14.7 | 13.7 | n.s. |
CAR09 | Cardiac arrhythmia | 14.1 | 11.1 | n.s. |
END06/07/08/09 | Diabetes | 10.1 | 11.4 | n.s. |
EAR08 | Deafness, hearing loss | 8.6 | 10.9 | n.s. |
CAR11 | Disorders of lipid metabolism | 6.4 | 11.4 | < 0.05 |
PSY19 | Sleep disorders of nonorganic origin | 8.9 | 10.8 | n.s. |
HEM02 | Iron deficiency, other deficiency anemias | 11.9 | 9.7 | n.s. |
EYE08 | Ischemic heart disease or AMIc | 11.6 | 9.1 | n.s. |
PSY09 | Glaucoma | 8.0 | 8.9 | n.s. |
END02 | Depression | 7.3 | 8.2 | n.s. |
CAR03 | Osteoporosis | 1.8 | 9.3 | <0.001 |
RES04 | Emphysema, chronic bronchitis, COPDd | 14.7 | 5.4 | <0.001 |
SKN02 | Dermatitis and eczema | 8.6 | 6.1 | n.s. |
HEM03 | Malignant neoplasms | 9.7 | 4.3 | <0.001 |
NUR21 | Thrombophlebitis | 3.4 | 5.8 | n.s. |
GUR04 | Neurologic disorders, other | 5.8 | 5.0 | n.s. |
RES11 | Prostatic hypertrophy | 24.2 | 0.0 | <0.001 |
EYE02 | Respiratory disorders, other | 7.0 | 4.2 | <0.05 |
MAL01 | Visual impairment | 5.5 | 4.6 | n.s. |
CAR16 | Skin/low impact neoplasms | 5.5 | 3.8 | n.s. |
END04 | Cardiovascular disorders, other | 3.1 | 3.9 | n.s. |
END05 | Hypothyroidism | 3.1 | 3.8 | n.s. |
REN01 | Other endocrine disorders | 1.8 | 4.1 | n.s. |
RHU02 | Chronic renal failure | 4.9 | 3.0 | n.s. |
NUT03 | Gout | 7.0 | 2.1 | <0.001 |
ADM02 | Obesity | 1.5 | 3.5 | n.s. |
CAR12 | Surgical aftercare | 3.4 | 2.8 | n.s. |
HEM08 | Hematologic disorders, other | 4.3 | 2.4 | n.s. |
ALL04/05 | Asthma | 1.5 | 3.1 | n.s. |
GAS10 | Diverticular disease of colon | 2.5 | 1.9 | n.s. |
PSY14 | Psychosocial disorders of childhood | 1.2 | 2.2 | n.s. |
PSY01 | Anxiety, neuroses | 1.2 | 2.0 | n.s. |
CAR06 | Cardiac valve disorders | 1.8 | 1.8 | n.s. |
MAL12 | Low back pain | 3.1 | 1.0 | <0.05 |
MUS14 | Irritable bowel syndrome | 0.9 | 1.3 | n.s. |
GAS09 | Seizure disorder | 2.1 | 1.0 | n.s. |
NUR07 | Utero-vaginal prolapse | 0.0 | 1.4 | <0.05 |
FRE12 | Parkinson’s disease | 1.5 | 1.0 | n.s. |
NUR06 | Gastroesophageal reflux | 0.6 | 1.2 | n.s. |
GAS08 | Peripheral neuropathy, neuritis | 0.6 | 1.2 | n.s. |
Drug use in centenarians
ATCa code | Chronic medication | Men (%) | Women (%) | P value |
---|---|---|---|---|
A02B | Drugs for peptic ulcer and GERDb | 53.9 | 50.2 | n.s.c |
B01A | Antithrombotic agents | 43.6 | 39.9 | n.s. |
N02B | Other analgesics and antipyretics | 34.1 | 36.4 | n.s. |
C03C | High-ceiling diuretics | 31.5 | 34.9 | n.s. |
N05B | Anxiolytics | 13.9 | 23.4 | <0.001 |
N06A | Antidepressants | 12.8 | 14.7 | n.s. |
N05C | Hypnotics and sedatives | 9.9 | 14.7 | <0.05 |
N05A | Antipsychotics | 11.4 | 14.2 | n.s. |
C09A | ACEd inhibitors, plain | 7.3 | 14.9 | <0.001 |
B03A | Iron preparations | 12.8 | 10.7 | n.s. |
C08C | Selective calcium channel blockers with mainly vascular effects | 13.9 | 10.3 | n.s. |
C05C | Capillary stabilizing agents | 4.4 | 11.4 | <0.05 |
C01D | Vasodilators used in cardiac diseases | 8.1 | 10.3 | n.s. |
C09C | Angiotensin II receptor blockers, plain | 7.0 | 9.0 | n.s. |
M02A | Topical products for joint and muscular pain | 6.1 | 9.0 | n.s. |
C09D | Angiotensin II receptor blockers, combinations | 5.9 | 8.4 | n.s. |
S01E | Antiglaucoma preparations and miotics | 7.7 | 7.3 | n.s. |
A06A | drugs for constipation | 8.1 | 6.7 | n.s. |
M01A | Antiinflammatory and antirheumatic products, non-steroids | 10.3 | 6.1 | <0.05 |
C01A | Cardiac glycosides | 8.1 | 6.6 | n.s. |
N06B | Psychostimulants, agents used for ADHDe and nootropics | 8.8 | 6.0 | n.s. |
R05C | Expectorants, excl. Combinations with cough suppressants | 8.4 | 5.5 | n.s. |
A10B | Blood glucose lowering drugs, excl. Insulins | 5.1 | 5.9 | n.s. |
V06X | General nutrients | 5.5 | 5.6 | n.s. |
B03B | Vitamin B12 and folic acid | 5.1 | 5.5 | n.s. |
C07A | Beta blocking agents | 4.4 | 5.7 | n.s. |
N02A | Opioids | 2.2 | 6.2 | <0.05 |
G04C | Drugs used in benign prostatic hypertrophy | 26.0 | 0.0 | <0.001 |
C10A | Lipid modifying agents, plain | 6.6 | 4.3 | n.s. |
C04A | Peripheral vasodilators | 5.5 | 4.1 | n.s. |
R03A | Adrenergics, inhalants | 7.3 | 3.7 | <0.05 |
R03B | Other drugs for obstructive airway diseases, inhalants | 7.3 | 3.7 | <0.05 |
S01X | Other ophthalmologicals | 3.7 | 4.4 | n.s. |
C09B | ACE inhibitors, combinations | 3.7 | 4.3 | n.s. |
D01A | Antifungals for topical use | 4.0 | 4.2 | n.s. |
C03D | Potassium-sparing agents | 5.9 | 3.6 | n.s. |
C03E | Diuretics and potassium-sparing agents in combination | 1.1 | 4.6 | <0.05 |
A03F | Propulsives | 1.1 | 4.1 | <0.05 |
R06A | Antihistamines for systemic use | 5.5 | 3.1 | n.s. |
C01E | Other cardiac preparations | 3.7 | 3.4 | n.s. |
C03B | Low-ceiling diuretics, excl. Thiazides | 2.6 | 3.6 | n.s. |
C08D | Selective calcium channel blockers with direct cardiac effects | 3.7 | 2.7 | n.s. |
A12A | Calcium | 0.7 | 3.3 | <0.05 |
A12B | Potassium | 1.8 | 3.1 | n.s. |
D07A | Corticosteroids, plain | 4.8 | 2.3 | <0.05 |
M04A | Antigout preparations | 5.9 | 2.0 | <0.001 |
N03A | Antiepileptics | 1.8 | 3.0 | n.s. |
N07C | Antivertigo preparations | 2.9 | 2.6 | n.s. |
J01 M | Quinolone antibacterials | 4.0 | 1.9 | n.s. |
H02A | Corticosteroids for systemic use, plain | 3.7 | 1.7 | n.s. |
H03A | Thyroid preparations | 1.1 | 2.3 | n.s. |
J01X | Other antibacterials | 2.9 | 1.4 | n.s. |
J01C | Beta-lactam antibacterials, penicillins | 2.6 | 1.4 | n.s. |
N06D | Anti-dementia drugs | 1.8 | 1.6 | n.s. |
V06Z | General nutrients | 2.9 | 1.4 | n.s. |
S01A | Antiinfectives | 0.7 | 1.7 | n.s. |
A10A | Insulins and analogues | 1.5 | 1.4 | n.s. |
C03A | Low-ceiling diuretics, thiazides | 0.7 | 1.4 | n.s. |
J01D | Other beta-lactam antibacterials | 1.1 | 1.4 | n.s. |
R05D | Cough suppressants, excl. Combinations with expectorants | 2.3 | 1.0 | n.s. |
H03B | Antithyroid preparations | 0.7 | 1.1 | n.s. |